Published in Drug Metab Dispos on December 01, 2008
Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol (2012) 2.33
PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci (2009) 2.32
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2011) 1.00
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS (2013) 0.95
Distinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a Chip. PLoS One (2016) 0.89
Heteroaromatic and aniline derivatives of piperidines as potent ligands for vesicular acetylcholine transporter. J Med Chem (2013) 0.88
Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nucl Med Biol (2011) 0.88
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci (2015) 0.85
Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. ACS Chem Neurosci (2014) 0.83
[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. EJNMMI Res (2012) 0.81
Cognition in movement disorders: where can we hope to be in ten years? Mov Disord (2014) 0.81
Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems. AAPS J (2011) 0.81
P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology (2013) 0.80
The Effect of Exercise Training on Resting Concentrations of Peripheral Brain-Derived Neurotrophic Factor (BDNF): A Meta-Analysis. PLoS One (2016) 0.79
A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer (2013) 0.79
A philosophy for CNS radiotracer design. Acc Chem Res (2014) 0.79
Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. PLoS One (2015) 0.79
Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci (2012) 0.79
Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Res (2012) 0.79
ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [ (11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig. EJNMMI Res (2014) 0.78
Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cells. Methods (2015) 0.78
An Isogenic Blood-Brain Barrier Model Comprising Brain Endothelial Cells, Astrocytes and Neurons Derived from Human Induced Pluripotent Stem Cells. J Neurochem (2016) 0.78
Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters. J Nucl Med (2011) 0.77
Synthesis and evaluation of new fluorine-18 labeled verapamil analogs to investigate the function of P-glycoprotein in the blood-brain barrier. ACS Chem Neurosci (2017) 0.76
Generation of Brain Microvascular Endothelial-Like Cells from Human Induced Pluripotent Stem Cells by Co-Culture with C6 Glioma Cells. PLoS One (2015) 0.76
Modeling Ischemic Stroke In Vitro: Status Quo and Future Perspectives. Stroke (2016) 0.76
A potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression. Org Biomol Chem (2015) 0.76
[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats. EJNMMI Res (2012) 0.76
A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans. Toxicol Appl Pharmacol (2016) 0.76
Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells. Fluids Barriers CNS (2017) 0.75
Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier. PLoS One (2016) 0.75
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach. AAPS J (2013) 0.75
Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. J Cereb Blood Flow Metab (2015) 0.75
Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling. J Cereb Blood Flow Metab (2011) 0.75
In Vitro Modeling of Blood-Brain Barrier with Human iPSC-Derived Endothelial Cells, Pericytes, Neurons, and Astrocytes via Notch Signaling. Stem Cell Reports (2017) 0.75
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med (2009) 3.83
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage (2004) 2.07
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology (2012) 2.02
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry (2002) 1.87
Rapid bone and blood flow formation in impacted morselized allografts: positron emission tomography (PET) studies on allografts in 5 femoral component revisions of total hip arthroplasty. Acta Orthop Scand (2003) 1.82
Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol (2010) 1.67
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol (2003) 1.65
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J Nucl Med (2008) 1.60
Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state. Eur J Pain (2008) 1.55
Morphine metabolism after major liver surgery. Anesth Analg (2007) 1.54
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet (2012) 1.48
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci (2008) 1.47
Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett (2004) 1.47
GMP--three letters with many interpretations. Protection of patients or killing the clinical and research applications of PET? Eur J Nucl Med Mol Imaging (2008) 1.39
Ventilation distribution studies comparing Technegas and "Gallgas" using 68GaCl3 as the label. J Nucl Med (2011) 1.39
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull (2007) 1.35
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
The relationship between cerebral blood flow and volume in humans. Neuroimage (2005) 1.29
Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep (2012) 1.28
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry (2004) 1.28
Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging (2010) 1.27
18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med (2011) 1.26
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36. Mol Imaging Biol (2013) 1.25
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging (2010) 1.24
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry (2005) 1.23
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med (2012) 1.19
Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear. Eur J Neurosci (2003) 1.18
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage (2006) 1.17
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med (2005) 1.16
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos (2010) 1.16
Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry (2007) 1.15
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage (2004) 1.14
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res (2003) 1.11
[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int (2008) 1.11
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med (2012) 1.09
In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos (2007) 1.09
Development of a (11)C-labeled tetrazine for rapid tetrazine-trans-cyclooctene ligation. Chem Commun (Camb) (2013) 1.08
The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res (2003) 1.08
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am (2003) 1.07
[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage (2006) 1.06
Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage (2002) 1.05
Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J Neurosci (2009) 1.04
Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis (2011) 1.04
A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage (2004) 1.03
Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology (2012) 1.02
Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A (2013) 1.02
Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos (2009) 1.01
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem (2009) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging (2010) 1.01
Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry (2010) 1.00
α4βδ GABA(A) receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Proc Natl Acad Sci U S A (2012) 0.99
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos (2006) 0.99
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage (2010) 0.98
Laser Doppler flowmetry is valid for measurement of cerebral blood flow autoregulation lower limit in rats. Exp Physiol (2005) 0.98
Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry (2010) 0.98
Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab (2009) 0.98
Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Med Imaging (2005) 0.98
Bone regeneration 6 years after impaction bone grafting: a PET analysis. Acta Orthop (2007) 0.98
Unidirectional Influx and Net Accumulation of PIB. Open Neuroimag J (2008) 0.98
Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos (2008) 0.98
Imaging of peptide adsorption to microfluidic channels in a plastic compact disc using a positron emitting radionuclide. Lab Chip (2005) 0.98
Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab (2003) 0.98
Cerebral blood flow and metabolism after cardiopulmonary resuscitation. A pathophysiologic and prognostic positron emission tomography pilot study. Resuscitation (2003) 0.97
Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry (2006) 0.97
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn (2012) 0.96
Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) (2010) 0.96
An incomplete TCA cycle increases survival of Salmonella Typhimurium during infection of resting and activated murine macrophages. PLoS One (2010) 0.96
Radical carbonylation with [11C]carbon monoxide promoted by oxygen-centered radicals: experimental and DFT studies of the mechanism. J Am Chem Soc (2007) 0.95
Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metab Dispos (2005) 0.95
Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci (2005) 0.95
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging (2009) 0.95
[(11)C] Carbon monoxide in selenium-mediated synthesis of (11)C-carbamoyl compounds. J Org Chem (2002) 0.95
Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol (2005) 0.95